10-Q: Beyond Air Reports Q1 2025 Results: Revenue Growth Amidst Ongoing Losses

Beyond Air's Q1 2025 results show increased revenue from LungFit PH sales, but the company continues to operate at a loss while investing in research and development.

Summary

• Beyond Air reported a net loss of $13.055 million for the quarter ended June 30, 2024, compared to a net loss of $15.055 million for the same period in 2023.
• Revenue increased significantly to $683,000, up from $59,000 in the prior year, primarily due to the commercial launch of LungFit PH.
• The company's operating expenses totaled $13.247 million, with research and development expenses at $6.009 million and selling, general, and administrative expenses at $7.239 million.
• Cash and cash equivalents, along with marketable securities, totaled $21.4 million as of June 30, 2024.
• The company used $10.2 million in operating activities during the quarter.
• Beyond Air has accumulated losses of $251.9 million attributable to stockholders.
• The company has various funding options in place, including a debt line of $12.5 million, an ATM sales agreement with $32.9 million available, and potential partnerships.
• Management believes the company will require additional funding within one year from the date these financial statements are issued.

Sentiment

Score: 4

Explanation: The document shows some positive signs with increased revenue and reduced operating expenses, but the significant net loss, negative cash flow, and the need for additional funding within a year create a negative outlook. The company is still in a high-risk phase of development and commercialization.

Positives

• Revenue increased significantly due to the commercial launch of LungFit PH.
• The net loss decreased compared to the same quarter last year.
• Selling, general, and administrative expenses decreased, indicating improved cost management.
• The company has multiple funding options available to support operations.
• Beyond Cancer's phase 1a trial showed no dose-limiting toxicities in the first 6 patients.

Negatives

• The company continues to operate at a loss, with a net loss of $13.055 million for the quarter.
• Operating expenses remain high, totaling $13.247 million.
• The company used $10.2 million in operating activities during the quarter.
• Management has stated that the company will require additional funding within one year.
• Cost of revenue exceeded revenue due to supply chain infrastructure and depreciation of LungFit devices.

Risks

• The company's ability to continue as a going concern is dependent on securing additional funding.
• There is no assurance that the company will be able to raise sufficient capital on acceptable terms.
• The company is subject to risks common to development and early-stage medical device companies.
• The company is dependent on third-party suppliers, including single-source suppliers.
• The company's products require regulatory approvals, and there is no guarantee that these will be obtained.
• The company's products may not be accepted in the marketplace.
• The company is subject to financial covenants, including maintaining $5.0 million in unrestricted cash.

Future Outlook

The company expects to incur net losses and have significant cash outflows for at least the next year, including making significant investments in research and development. Management believes the company will require additional funding within one year. The company anticipates entering the final phase of its launch process in calendar 2025 where it intends to equip its commercial organization to become the market leader in the U.S. in a few years. The company expects its nNOS program to progress from preclinical to a phase 1 first-in-human clinical trial by the end of 2025. The company anticipates commencing a pivotal clinical trial for NTM in calendar year 2026 following discussions with the FDA.

Management Comments

• Management believes these factors raise substantial doubt about the Company's ability to meet its obligations with cash on hand and concluded that the Company will require additional funding within one year from the date these financial statements are issued.
• Management is confident that the efforts to arrange financing as described below, while not assured, will enable the Company to meet its obligations.

Industry Context

The company operates in the medical device and biopharmaceutical industry, focusing on nitric oxide (NO) therapies. The market for NO therapies is competitive, with Mallinckrodt Pharmaceuticals being a major player in the U.S. The company's LungFit platform aims to provide a competitive advantage by generating NO from ambient air, eliminating the need for high-pressure cylinders. The company is also targeting unmet medical needs in areas such as viral pneumonia, bronchiolitis, and NTM lung infections.

Comparison to Industry Standards

• Mallinckrodt Pharmaceuticals reported sales of NO at $303.2 million in 2023, with over 90% in the U.S., indicating the size of the market Beyond Air is targeting with LungFit PH.
• The company's LungFit PH is the first FDA-approved system using its patented plasma pulse technology to generate on-demand NO from ambient air, which is a differentiator from traditional NO delivery systems.
• The company's focus on high-concentration NO delivery for microbial infections is a novel approach compared to current FDA-approved NO vasodilation treatments.
• The company's clinical trial results for VCAP and bronchiolitis show promising trends in shortening length of stay and improving oxygen saturation, which are key metrics in these indications.
• The company's preclinical data for UNO in solid tumors shows potential for combination therapies with immune checkpoint inhibitors, which is a growing area of research in oncology.

Management Changes

Related Party Transactions

• Members of the Board of the Directors and certain executives of the Company are considered related parties to the March 20, 2024 offering.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential equity offerings.
• Employees may be impacted by the company's financial situation and potential restructuring.
• Customers may benefit from the company's products, but the company's financial stability could affect product availability.
• Suppliers may be impacted by the company's financial situation and ability to pay for materials.
• Creditors face the risk of non-payment if the company is unable to secure additional funding.

Next Steps

• The company will continue to commercialize LungFit PH in the U.S.
• The company expects to receive CE mark under the Medical Device Regulation (MDR) in the EU during the second half of calendar 2024.
• The company will continue to work towards a potential launch in the EU and globally in 2024 and beyond.
• The company anticipates entering the final phase of its launch process in calendar 2025.
• The company expects its nNOS program to progress into a phase 1 first-in-human clinical trial by the end of 2025.
• The company anticipates commencing a pivotal clinical trial for NTM in calendar year 2026 following discussions with the FDA.

Key Dates

Keywords

LungFit PH, nitric oxide, PPHN, medical device, biopharmaceutical, Beyond Cancer, clinical trials, revenue, net loss, funding, research and development, commercialization